Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer

Lilly

Status and phase: Completed; Phase 2

Conditions: Non-Small-Cell Lung Cancer

Treatments: Drug: LY573636-sodium

Study type: Interventional

Funder types: Industry

Identifiers

NCT00363766

9813

H8K-MC-JZAC (Other Identifier)

Details and patient eligibility

About

The primary objective is to estimate the time to progressive disease for patients who receive LY573636-sodium (hereafter referred to as LY573636) after two previous treatments for metastatic non-small cell lung cancer. Patients will receive an intravenous infusion of study drug once every 21 days. Computed tomography (CT)-scans will be done before the first dose and then after every other treatment.

Enrollment: 52 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of metastatic non-small-cell lung cancer
• At least 18 years of age
• Have received 2 previous treatment regimens for metastatic non-small-cell lung cancer

Exclusion criteria

• Serious pre-existing medical conditions
• Previous cancer (except skin cancer, excluding melanoma)
• Have received 3 or more previous treatment regimens for metastatic non- small-cell lung cancer
• Active treatment with Coumadin

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

52 participants in 1 patient group

LY573636

Experimental group

Treatment:

Drug: LY573636-sodium